Skip to main content

Table 3 Characteristics of 242 children in the Nordic JIA cohort according to PE participation at the 8 year visita

From: Participation in school and physical education in juvenile idiopathic arthritis in a Nordic long-term cohort study

Characteristics at the eight-year visit Total
n
Full PE
(n = 194)
Partly or no PE
(n = 48)
OR (95% CI) P-value
Females, n (%) 242 119 (61.3) 39 (81.3) 2.7 (1.3–6.0) 0.012
Age at disease onset, years 242 4.4 (2.2–7.3) 4.6 (2.3–8.7) 1.0 (0.9–1.1) 0.398
BMI 205 18.9 (16.8–21.0) 21.2 (17.8–23.5) 1.1 (1.0–1.2) 0.013
Cumulative joint count 242 5 (2–9) 12 (4–16) 1.1 (1.0–1.1) < 0.001
Active joints 242 0 (0–0) 0 (0–2) 2.0 (1.4–2.8) < 0.001
Physician GA, VAS 188 0.0 (0.0–0.5) 0.9 (0.2–2.0) 7.1 (2.7–18.8) < 0.001
Patient/parent GA, VAS 212 0.0 (0.0–0.4) 1.6 (0.3–3.4) 6.1 (2.9–12.6) < 0.001
Pain VAS 216 0.0 (0.0–0.5) 2.0 (0.8–5.6) 7.8 (3.8–15.9) < 0.001
CHAQ score 242 0.0 (0.0–0.0) 0.3 (0.0–1.0) 15.0 (5.9–38.6) < 0.001
CHQ-PF50, PhS score 156 53.9 (48.5–57.3) 41.5 (31.1–48.2) 0.9 (0.8–0.9) < 0.001
CHQ-PF50, PsS score 156 56.0 (49.9–60.1) 50.3 (44.6–55.8) 0.9 (0.9–1.0) 0.010
DMARDs, n (%) 242 64 (33.0) 24 (50.0) 1.5 (1.1–2.2) 0.025
JADAS10 147 0.1 (0.0–1.9) 4.7 (1.9–8.0) 1.5 (1.3–1.7) < 0.001
Not in remission, n (%) 236 106 (55.8) 42 (91.3) 6.5 (2.5–17.2) < 0.001
ESR mm/hour 164 7.0 (4.0–10.0) 12.0 (5.0–16.0) 1.1 (1.0–1.1) 0.029
CRP mg/liter 169 0.0 (0.0–5.0) 0.0 (0.0–5.0) 1.0 (0.9–1.0) 0.851
RF positive, n (%) 123 1.0 (1.1) 0 n.a n.a
HLA-B27 positive, n (%) 233 42 (22.6) 10 (21.3) 0.9 (0.4–2.0) 0.848
ANA positive, n (%) 241 51 (26.4) 8 (16.7) 0.6 (0.2–1.3) 0.164
  1. aPatient-/ proxy-reported participation in physical education due to JIA during the preceding 2 months of the eight-year study visit, univariate logistic regression. Values are the median (interquartile range, IQR), unless indicated otherwise, OR Odds ratio, CI Confidence interval, GA Global assessment, VAS Visual analogue scale, CHAQ Childhood health assessment questionnaire, CHQ-PF50 Child health questionnaire parent form, PhS Physical summary score, PsS Psychological summary score, DMARDs Disease-modifying antirheumatic drugs including biologics used at the final study visit, Not in remission Not in remission off medication according to the Wallace preliminary criteria [21], ESR Erythrocyte sedimentation rate, CRP C-reactive protein, RF Rheumatoid factor, assessed twice with at least 3 months interval, n.a. Not applicable, HLA-B27 Human leucocyte antigen, ANA Antinuclear antibody, assessed twice with at least 3 months interval